Randomized, double blind, controlled phase I trial of the safety, tolerability and immunogenicity of Fluzone inactivated trivalent influenza virus vaccine administered with ascending doses of JVRS-100 adjuvant

Trial Profile

Randomized, double blind, controlled phase I trial of the safety, tolerability and immunogenicity of Fluzone inactivated trivalent influenza virus vaccine administered with ascending doses of JVRS-100 adjuvant

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Jun 2015

At a glance

  • Drugs JVRS 100 (Primary) ; Influenza virus vaccine
  • Indications Influenza virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Juvaris BioTherapeutics
  • Most Recent Events

    • 15 Mar 2010 Company added as trial sponsor as reported by ClinicalTrials.gov.
    • 15 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Apr 2009 Results will be presented at the National Foundation for Infectious Diseases 12th Annual Conference on Vaccine Research, according to a Juvaris BioTherapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top